東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Evidence Supporting FDA Approval and...

Roginiel, Aliya C.

FindBook

Google Book

Amazon

博客來

Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study./
作者:	Roginiel, Aliya C.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	43 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-02, Section: A.
Contained By:	Dissertations Abstracts International81-02A.
標題:	Medicine. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13809740
ISBN:	9781085557450

Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study.
Roginiel, Aliya C.

Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 43 p.

Source: Dissertations Abstracts International, Volume: 81-02, Section: A.

Thesis (M.D.)--Yale University, 2019.

This item must not be sold to any third party vendors.

Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) rely on evidence from clinical trials when approving a therapeutic for marketing and insurance coverage in the US, respectively. No study has compared the quality and quantity of evidence examined by these agencies. Our purpose was to characterize evidence used by FDA and CMS to support marketing approval and coverage of novel therapeutics reviewed for CMS coverage from 2005 through 2016.We conducted a cross-sectional study of clinical trials described in FDA approval documents and CMS NCD memoranda. We compared the number of clinical trials used by each agency as well as the following characteristics of clinical trials: study size, randomization, double-blinding, and control arm. Twelve medical products met our inclusion criteria. FDA approvals were based on 22 pivotal trials. CMS NCDs were based on 27 original clinical trials; 14 clinical trials were used by both agencies. Between FDA pivotal and CMS original clinical trials, there was no significant difference in study size (P = .53), use of randomization (P = .75), double-blinding (P = .55), or control arm (P = .54). There was no statistically significant difference in median age between participants in trials reviewed by CMS versus those reviewed by FDA (62 vs 59 years, P = .26). The median time from FDA approval to publication of CMS NCD memorandum was 17 (interquartile range, 13-36) months. FDA approvals and CMS NCDs are based on a similar number and quality of trials, although trial participants are not reflective of the Medicare population, and the process of finalizing coverage determinations requires an additional 17 months.

ISBN: 9781085557450Subjects--Topical Terms:

641104
Medicine.

Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study.
LDR:02835nmm a2200325 4500 001 2262990
005 20191121113954.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781085557450
035 $a (MiAaPQ)AAI13809740
035 $a AAI13809740
040 $a MiAaPQ $c MiAaPQ
100 1 $a Roginiel, Aliya C. $3 3540063
245 1 0 $a Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 43 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-02, Section: A.
500 $a Advisor: Ross, Joseph S.
502 $a Thesis (M.D.)--Yale University, 2019.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) rely on evidence from clinical trials when approving a therapeutic for marketing and insurance coverage in the US, respectively. No study has compared the quality and quantity of evidence examined by these agencies. Our purpose was to characterize evidence used by FDA and CMS to support marketing approval and coverage of novel therapeutics reviewed for CMS coverage from 2005 through 2016.We conducted a cross-sectional study of clinical trials described in FDA approval documents and CMS NCD memoranda. We compared the number of clinical trials used by each agency as well as the following characteristics of clinical trials: study size, randomization, double-blinding, and control arm. Twelve medical products met our inclusion criteria. FDA approvals were based on 22 pivotal trials. CMS NCDs were based on 27 original clinical trials; 14 clinical trials were used by both agencies. Between FDA pivotal and CMS original clinical trials, there was no significant difference in study size (P = .53), use of randomization (P = .75), double-blinding (P = .55), or control arm (P = .54). There was no statistically significant difference in median age between participants in trials reviewed by CMS versus those reviewed by FDA (62 vs 59 years, P = .26). The median time from FDA approval to publication of CMS NCD memorandum was 17 (interquartile range, 13-36) months. FDA approvals and CMS NCDs are based on a similar number and quality of trials, although trial participants are not reflective of the Medicare population, and the process of finalizing coverage determinations requires an additional 17 months.
590 $a School code: 0265.
650 4 $a Medicine. $3 641104
650 4 $a Public policy. $3 532803
650 4 $a Public health. $3 534748
690 $a 0564
690 $a 0630
690 $a 0573
710 2 $a Yale University. $b Yale School of Medicine. $3 3422308
773 0 $t Dissertations Abstracts International $g 81-02A.
790 $a 0265
791 $a M.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13809740